 The risk of thrombotic complications after implantation of drug-eluting stents DES in coronary arteries may be increased in patients with diabetes mellitus DM or metabolic syndrome MS. It is recommended that all patients take an association of aspirin and clopidogrel for several months after DES implantation to reduce this risk. However, the biological efficacy of current antiplatelet therapies has not been studied prospectively and specifically in DM or MS patients. 